Shun Lu
Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai Chest Hospital, Shanghai Jiaotong University · Shanghai Chest Hospital, China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Shun Lu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:18 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07668752 · A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationGenfleet Therapeutics (Shanghai) Inc. · recruiting · KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer) · principal investigator
- N/ANCT07624318 · TROP2 NMR Concordance StudyAstraZeneca · recruiting · Lung Cancer · principal investigator
- Ph1NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung CancerShanghai AbelZeta Ltd. · recruiting · Squamous Cell Lung Cancer · principal investigator
- Ph3NCT07174908 · A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C MutationInxMed (Shanghai) Co., Ltd. · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT07110883 · A Clinical Study of SYS6023 in Patients With Advanced Solid TumorsCSPC Megalith Biopharmaceutical Co.,Ltd. · recruiting · Advanced Solid Tumor · study chair
- Ph1NCT07110363 · A Clinical Study of BT02 in Treating Patients With Advanced Lung CancerBiotroy Therapeutics · not yet recruiting · Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT07063329 · Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positiveAvistone Pharmaceutical(Ningbo)Co., LTD. · recruiting · NSCLC (Non-small Cell Lung Cancer) · principal investigator
- Ph3NCT06927986 · Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)CSPC Megalith Biopharmaceutical Co.,Ltd. · recruiting · EGFR-mutated Locally Advanced or Metastatic NSCLC · principal investigator
- Ph2NCT06737081 · SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid MalignanciesShenzhen Salubris Pharmaceuticals Co., Ltd. · recruiting · Anemia · principal investigator
- Ph1/Ph2NCT06500676 · A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D MutationsGenfleet Therapeutics (Shanghai) Inc. · recruiting · KRAS G12D Mutations, Advanced Solid Tumors · principal investigator
- Ph1NCT06468098 · A Study of IBI363 in Subjects With Advanced MalignanciesInnovent Biologics (Suzhou) Co. Ltd. · recruiting · Advanced Malignancies · principal investigator
- N/ANCT06443684 · A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLCShanghai Chest Hospital · active not recruiting · Non Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT06373406 · A Study of MHB036C for Advanced Solid TumorMinghui Pharmaceutical (Hangzhou) Ltd · active not recruiting · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT06345482 · A Study of MHB039A for Advanced Solid TumorMinghui Pharmaceutical (Hangzhou) Ltd · active not recruiting · Advanced Solid Tumor · principal investigator
- Ph1NCT06328439 · A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid TumorsAvistone Biotechnology Co., Ltd. · active not recruiting · Locally Advanced or Metastatic Solid Tumors · principal investigator
- Ph2NCT06147570 · A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerJiangsu Hansoh Pharmaceutical Co., Ltd. · recruiting · Nonsmall Cell Lung Cancer · principal investigator
- Ph3NCT06041776 · Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsBetta Pharmaceuticals Co., Ltd. · recruiting · Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy · study chair
- Ph1NCT06015568 · Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationBetta Pharmaceuticals Co., Ltd. · not yet recruiting · Non-Small Cell Lung Cancer、EGFR Sensitive Mutation · study chair
- Ph1/Ph2NCT05951608 · A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid TumorsAkeso · active not recruiting · Advanced Solid Tumors · principal investigator
- Ph1NCT05911464 · A Phase I Study of HS-10386 in Participants With Advanced Solid TumorsJiangsu Hansoh Pharmaceutical Co., Ltd. · recruiting · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT05731518 · SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Biocity Biopharmaceutics Co., Ltd. · unknown · Small Cell Lung Cancer · study chair
- Ph1/Ph2NCT05641493 · A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationShanghai Henlius Biotech · unknown · Non Small Cell Lung Cancer · principal investigator
- Ph1NCT05430386 · Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLCJiangsu Hansoh Pharmaceutical Co., Ltd. · unknown · Non Small Cell Lung Cancer · principal investigator
- Ph1NCT05393063 · A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid TumorsAkeso · unknown · Advanced Solid Tumors · principal investigator
- Ph1/Ph2NCT05383898 · Study to Evaluate D-1553 in Subjects With Lung CancerInventisBio Co., Ltd · completed · NSCLC · principal investigator
- Ph2NCT05374603 · Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCAstraZeneca · active not recruiting · Lung Cancer · principal investigator
- Ph3NCT05261399 · Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentAstraZeneca · active not recruiting · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph1NCT05223595 · A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLCChangchun GeneScience Pharmaceutical Co., Ltd. · unknown · Metastatic Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05207787 · Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid TumorsJiangsu Hansoh Pharmaceutical Co., Ltd. · unknown · Solid Tumor · principal investigator
- Ph2NCT05141786 · A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).Shanghai Miracogen Inc. · unknown · Non-small- Cell Lung Cancer (NSCLC) · principal investigator
- Ph1NCT05116007 · Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLCAkeso · completed · SCLC, Extensive Stage · principal investigator
- Ph2NCT05078931 · A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC PatientsShanghai Chest Hospital · active not recruiting · NSCLC · principal investigator
- Ph1NCT05055232 · A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerXuanzhu Biopharmaceutical Co., Ltd. · completed · ROS1 Rearrangement Non-small Cell Lung Cancer, ALK Rearrangement Non-small Cell Lung Cancer · principal investigator
- Ph3NCT05015608 · Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationHutchison Medipharma Limited · completed · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT04923906 · Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsJiangsu Hansoh Pharmaceutical Co., Ltd. · active not recruiting · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT04923945 · Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) PatientsHutchison Medipharma Limited · completed · Non-small Cell Lung Cancer Metastatic · principal investigator
- Ph1NCT04866485 · A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 AntibodyHarbour BioMed (Guangzhou) Co. Ltd. · unknown · Solid Tumor · principal investigator
- Ph1NCT04671849 · An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.Jiangsu Simcere Pharmaceutical Co., Ltd. · terminated · Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion · principal investigator
- Ph1NCT04477057 · PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid TumorsJiangsu Hansoh Pharmaceutical Co., Ltd. · unknown · Solid Tumor · principal investigator
- Ph2NCT04290325 · HMPL-453 in Advanced Malignant MesotheliomaHutchison Medipharma Limited · unknown · Advanced Malignant Mesothelioma · principal investigator
- Ph2/Ph3NCT04206072 · D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCBetta Pharmaceuticals Co., Ltd. · completed · Non-Small Cell Lung Cancer, EGFR Gene Mutation · principal investigator
- N/ANCT04197076 · Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIBShanghai Chest Hospital · unknown · Non Small Cell Lung Cancer · study chair
- Ph3NCT04158440 · Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLCShanghai Junshi Bioscience Co., Ltd. · completed · Stage II-III Non-small Cell Lung Cancer · principal investigator
- Ph1NCT03976856 · Safety and Efficacy of Genolimzumab (GB226) in Combination With FruquintinibGenor Biopharma Co., Ltd. · unknown · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03861156 · D-0316 in Patients With EGFR Positive Non Small Cell Lung CancerInventisBio Co., Ltd · completed · Solid Tumor, NSCLC, EGFR T790M · study chair
- Ph2NCT03777124 · Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerJiangsu HengRui Medicine Co., Ltd. · terminated · NSCLC Stage IV, KRAS Gene Mutation, PD-1 Antibody · principal investigator
- Ph2NCT03608007 · X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene RearrangementBetta Pharmaceuticals Co., Ltd. · unknown · Lung Cancer, ROS1 Gene Rearrangement · principal investigator
- N/ANCT03546452 · A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLCShanghai Chest Hospital · unknown · Malignant Hydrothorax, NSCLC · principal investigator
- Ph3NCT03521154 · A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)AstraZeneca · active not recruiting · Non Small Cell Lung Cancer (Stage III) · principal investigator
- N/ANCT03059641 · Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaGeneplus-Beijing Co. Ltd. · completed · Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung · principal investigator
- N/ANCT03029858 · PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC PatientsGuangdong Association of Clinical Trials · unknown · Small Cell Lung Cancer, Polygonal Type · principal investigator
- N/ANCT02980536 · cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia ChinaBerry Genomics Co., Ltd. · unknown · Nonsmall Cell Lung Cancer, Adenocarcinoma · study chair
- Ph2NCT02897479 · A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerHutchison Medipharma Limited · unknown · Lung Sarcomatoid Carcinoma · principal investigator
- Ph4NCT02348450 · Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung CancerGuangdong Association of Clinical Trials · unknown · Small Cell Lung Cancer · principal investigator
- Ph2NCT02027090 · High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph3NCT01404260 · Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung CancerGuangdong Association of Clinical Trials · completed · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT00912392 · Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd · completed · Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:18 UTC. The ranking covers the 200 most relevant of 635 PubMed records, and a shared surname and initials can bring in a namesake. All 635 on PubMed
- A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med · 20203,522 citationsRCR 201.4
- 3,498 citationsRCR 88.2
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.N Engl J Med · 20222,541 citationsRCR 184.1
- Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.N Engl J Med · 20201,582 citationsRCR 68.6
- 1,313 citationsRCR 39.5
- 1,167 citationsRCR 61.6
- Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.N Engl J Med · 2023638 citationsRCR 53.7
- Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial.J Am Coll Cardiol · 2018555 citationsRCR 24.3
- Perioperative Nivolumab in Resectable Lung Cancer.N Engl J Med · 2024535 citationsRCR 59.3
- 441 citationsRCR 52.6